Ironwood Pharmaceuticals Inc (IRWD) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Ironwood Pharmaceuticals reported revenue of $296.2M, down 15.7% from $351.4M the year before. Net income was $24.0M (a 8.1% net margin), or $0.15 per diluted share. Gross margin was 33.3% and operating margin was 33.3%. Operating activities generated $127.0M of cash, leaving $127.0M of free cash flow. At fiscal year end, Ironwood Pharmaceuticals held $396.9M in total assets against $658.7M in total liabilities, including $215.5M of cash and equivalents.
Open the full interactive Ironwood Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Ironwood Pharmaceuticals Key Stats
| Share Price | $3.59 |
|---|---|
| Market Cap | $600.2M |
| P/E Ratio | 23.9 |
| Revenue YoY Growth | -15.7% |
| 52-Week Range | $1.43 – $5.39 |
| Shares Outstanding | 164.4 million (basic, 2026 Q2) |
Ironwood Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $389.5M | $413.8M | $410.6M | $442.7M | $351.4M | $296.2M |
| Cost of Goods Sold | $3.1M | $181.5M | — | $1.39B | $258.3M | $197.6M |
| Gross Profit | $386.4M | $232.3M | — | -$945.4M | $93.1M | $98.5M |
| Operating Income | $142.9M | $232.3M | $250.3M | -$945.4M | $93.1M | $98.5M |
| Pre-Tax Income | $108.9M | $200.7M | $252.4M | -$948.1M | $65.2M | $70.0M |
| Income Tax | $2.7M | -$327.8M | $77.4M | $83.5M | $64.3M | $46.0M |
| Net Income | $106.2M | $528.4M | $175.1M | -$1.00B | $880,000 | $24.0M |
| Diluted EPS | $0.66 | $3.21 | $0.96 | -$6.45 | $0.01 | $0.15 |
Ironwood Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $122.1M | $47.7M | $106.5M | $113.0M |
| Net Income | $40.1M | -$2.3M | $40.8M | $51.3M |
| Diluted EPS | $0.23 | -$0.01 | $0.24 | $0.31 |
Ironwood Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $362.6M | $620.1M | $656.2M | $92.2M | $88.6M | $215.5M |
| Current Assets | $495.8M | $745.2M | $780.6M | $233.3M | $182.4M | $274.2M |
| Total Assets | $559.2M | $1.13B | $1.10B | $471.1M | $350.9M | $396.9M |
| Current Liabilities | $32.2M | $161.7M | $25.5M | $276.1M | $38.8M | $242.2M |
| Total Long-Term Debt | $430.3M | $454.2M | $396.3M | $697.9M | $584.0M | $385.0M |
| Total Liabilities | $496.6M | $521.0M | $448.1M | $817.4M | $652.2M | $658.7M |
| Shareholders' Equity | $62.6M | $605.9M | $652.4M | -$346.3M | -$301.3M | -$261.8M |
Ironwood Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $168.8M | $261.9M | $273.8M | $183.4M | $103.5M | $127.0M |
| Cash From Investing | -$1.8M | -$265,000 | -$136,000 | -$1.03B | -$142,000 | -$34,000 |
| Cash From Financing | $18.5M | -$4.5M | -$237.6M | $277.2M | -$107.0M | $216,000 |
| Free Cash Flow | $167.0M | $261.6M | $273.6M | $183.2M | $103.4M | $127.0M |
Figures from Ironwood Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Ironwood Pharmaceuticals financials page for every line item.
Ironwood Pharmaceuticals Company Profile
| Ticker | IRWD |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer, smaller reporting company |
| SEC CIK | 0001446847 |
Frequently Asked Questions
What was Ironwood Pharmaceuticals' revenue in fiscal 2025?
Ironwood Pharmaceuticals (IRWD) reported revenue of $296.2M for fiscal 2025.
What is Ironwood Pharmaceuticals' annual revenue history?
Ironwood Pharmaceuticals' annual revenue by fiscal year: 2020: $389.5M; 2021: $413.8M; 2022: $410.6M; 2023: $442.7M; 2024: $351.4M; 2025: $296.2M.
What was Ironwood Pharmaceuticals' net income in fiscal 2025?
Ironwood Pharmaceuticals reported net income of $24.0M for fiscal 2025.
What was Ironwood Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Ironwood Pharmaceuticals' diluted EPS was $0.15 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Ironwood Pharmaceuticals generate in fiscal 2025?
Ironwood Pharmaceuticals generated $127.0M of free cash flow in fiscal 2025.
What was Ironwood Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Ironwood Pharmaceuticals reported revenue of $113.0M.
How much debt does Ironwood Pharmaceuticals have?
Ironwood Pharmaceuticals reported $385.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Ironwood Pharmaceuticals are outstanding?
Ironwood Pharmaceuticals reported a weighted average of 164.4 million basic shares outstanding in 2026 Q2.
What is Ironwood Pharmaceuticals' market cap?
Based on its latest closing price, Ironwood Pharmaceuticals (IRWD) has a market capitalization of about $600.2M.
When does Ironwood Pharmaceuticals' fiscal year end?
Ironwood Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Ironwood Pharmaceuticals headquartered?
Ironwood Pharmaceuticals lists its business address in Boston, Massachusetts in its SEC filings.